BioNTech Sues Moderna Over COVID-19 Vaccine Technology Patent

MT Newswires Live
02/20

BioNTech (BNTX) sued rival Moderna (MRNA) for allegedly directly and willfully infringing at least one of its patents related to its COVID-19 vaccine technology, according to a lawsuit filed Thursday.

The biotech firm alleged Moderna's mNEXSPIKE COVID-19 vaccine "exploits BioNTech's streamlined, domain-based COVID-19 vaccine technology claimed and protected" by a patent.

Even as Moderna uses the patent technology, the company "has not sought a license from BioNTech," but "profited and will continue to profit from its unauthorized and unlicensed use" of BioNTech's technology, BioNTech said in the lawsuit.

BioNTech demanded it be rewarded "all damages adequate to compensate it for Moderna's infringement" and a jury trial if necessary, according to the lawsuit.

Moderna did not immediately reply to MT Newswires' request for comment.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10